Clinical Trial

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2025-04-30; most recent amendment 2026-01-16.
Status change: Recruiting → Active, Not Recruiting 2025-12-01
Status change: Not Yet Recruiting → Recruiting 2025-06-10
Trial Details
NCT Number NCT06956235
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Hidradenitis Suppurativa
Enrollment 147 participants
Start Date 2025-06-09
Primary Completion 2026-11-16 (estimated)
Study Completion 2029-01-22 (estimated)
Updated on ClinicalTrials.gov 2026-01-20